76 Potential mechanisms of resistance identified through analysis of multiple biomarkers in immune hot non-responders with non-small cell lung cancer (NSCLC) treated with tislelizumab

• Yun Zhang,
• Wei Tan,
• Qing Zhou,
• Jayesh Desai,
• Juan Zhang,
• Yi-Long Wu,
• Sanjeev Deva,
• Jun Zhao,
• Xiaopeng Ma,
• Zhirong Shen,
• Xikun Wu,
• Shiangjiin Leaw

Affiliations

Yun Zhang

1 Clinical Medicine Department, Fujian Health College, Fuzhou, China

Wei Tan

6Beigene (Shanghai) Co., Ltd., Shanghai, China

Qing Zhou

6 Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China

Jayesh Desai

Aff548 grid.1055.10000000403978434Royal Melbourne Hospital and Peter MacCallum Cancer Centre Melbourne Victoria Australia

Juan Zhang

Aff2 0000 0001 0125 2443grid.8547.eThe Liver Cancer Institute, Zhongshan Hospital and Shanghai Medical School, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education 180 Fenglin Road 200032 Shanghai People’s Republic of China

Yi-Long Wu

6 Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China

Sanjeev Deva

2 Auckland City Hospital, Auckland, New Zealand

Jun Zhao

1 COVID-19 Research Center, Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210002, China

Xiaopeng Ma

7Beigene (Beijing) Co., Ltd., Beijing, China

Zhirong Shen

7Beigene (Beijing) Co., Ltd., Beijing, China

Xikun Wu

6Beigene (Shanghai) Co., Ltd., Shanghai, China

Shiangjiin Leaw

6Beigene (Shanghai) Co., Ltd., Shanghai, China